Form 4: Intellia Therapeutics Executive Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Jing L. Marantz, EVP, Chief Medical Officer of Intellia Therapeutics, Inc., reported multiple transactions in common stock on October 26, 2026.

Summary

  • Grant/award: acquired 199,822 Common Stock on October 26, 2026; holds 199,822 after (Direct).
  • Grant/award: acquired 275,061 Stock Option (right to buy) on October 26, 2026; holds 275,061 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Jing L. Marantz — Officer (EVP, Chief Medical Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-10-26Grant/awardCommon Stock199,822——199,822
2026-10-26Grant/awardStock Option (right to buy)275,061——275,061

Key Dates

DateDescription
2026-10-26Grant/award (199,822 shares)
2026-10-26Grant/award (275,061 shares)

Keywords

insider transaction, Form 4, NTLA, Intellia Therapeutics, Inc., neutral, Jing L. Marantz

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.